· rebuilt nightly from public records
Signal Sheet
Transcode Therapeutics is a publicly listed pharmaceutical preparations company in Boston, Massachusetts. It raised $8M in Dec 2024 and its filings name 4 officers. Everything below links to the record it came from.
The easy button for new customers
Lakewave's AI keeps accounts like this one coming. Your pipeline refills while you sleep.
Every night it scans funding, filings, new officers, hiring, contracts, permits and bids, finds the accounts that fit what you sell, and delivers each with outreach and a pursuit plan. Just need a list? Its AI waterfall builds one with verified, reachable contacts.
The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names
| Role | Contact | Source | Why they matter now |
|---|---|---|---|
| Executive Officer | Thomas A. Fitzgerald | SEC filing, Dec 2024 | Named officer in the filing; part of the buying group |
| Chief Technology Officer | Erik Manting | SEC filing, Dec 2024 | Technology and tooling decisions |
| Chief Technology Officer | Magda Marquet | SEC filing, Dec 2024 | Technology and tooling decisions |
| Chief Technology Officer | Philippe Calais | SEC filing, Dec 2024 | Technology and tooling decisions |
| Chief Executive Officer | Find with a free trial | Lakewave contact search | Signs off on new vendors; budget owner |
| Chief Financial Officer | Find with a free trial | Lakewave contact search | Approves spend after a raise |
Signed a material agreement
Corporate eventOfficer or director change
New leadershipEquity raise reported to the SEC, Dec 2024. Money arrives before the spending plan does.
CapitalThe most recent events first, refreshed every night. Each links to the record it came from.
| When | What happened | Kind | Source |
|---|---|---|---|
| Oct 1, 2026 | Signed a material agreement | Corporate event | SEC filing |
| Sep 9, 2026 | Officer or director change | New leadership | SEC filing |
| Dec 2, 2024 | Raised $8M in equity from 6 investors | Capital | SEC filing |
Lakewave finds the right people at Transcode Therapeutics, checks every address against the mail server before you see it, and drafts a first email for each, which you review and send from your own inbox.
Try it on Transcode Therapeutics with a free trial →| Headquarters | Boston, Massachusetts, per the filing address |
| Industry group | Pharmaceutical Preparations |
| Ownership | Listed company |
| Raise history | $8M (Dec 2024) |
Private-sector companies in the same industry group and state, ranked by Rising score.
Yes. Transcode Therapeutics reported a $8M equity raise to the SEC on Dec 2, 2024 with 6 investors.
The company's SEC filing, Dec 2024 names Thomas A. Fitzgerald (Executive Officer) among its officers.
Boston, Massachusetts, per the address on its SEC filing.
Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.
Start your free trialCompiled from public records and refreshed nightly; last updated Nov 16, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.